A blood thinner combo tested for heart surgery patients who cannot tolerate heparin
NCT ID NCT07817680
First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time
Summary
Heparin-induced thrombocytopenia (HIT) is a rare immune reaction that makes heparin dangerous, yet heart bypass surgery normally depends on heparin to keep the machine from clotting. Doctors at 11 French cardiac surgery centers are reviewing past cases where patients with confirmed HIT received cangrelor, an intravenous blood thinner, alongside heparin during bypass. The study measures major bleeding and clotting events within seven days after surgery and describes how cangrelor was dosed and monitored. It aims to describe whether this combination is safe and effective, not to prove it in a controlled trial.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- cangrelor, an intravenous blood thinner given with heparin during heart bypass surgery
- What this could lead to
- If cangrelor proves safe and effective here, it could give heart surgeons a workable option for patients who cannot safely receive heparin alone.
- What could go wrong
- This is a retrospective review of past cases, not a controlled experiment, so it can show patterns but cannot prove cause and effect. Bleeding and clotting remain serious risks in this fragile group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 132 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Nov 2026
An estimate. Start dates often move.
- Expected to finish
-
Feb 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
* Age \< 18 years * HIT not confirmed or ruled out * Patient objection to data use * Surgery performed without CPB * Requirement for continued cangrelor in the postoperative period * Post-cardiotomy ECMO
- Ages
-
18 years and older
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 18 years * Confirmed or highly probable HIT: 4T score ≥ 3 AND positive anti-PF4 antibodies (ELISA or equivalent), and when available, positive functional platelet test * Cardiac or aortic surgery with cardiopulmonary bypass (CPB) * Cangrelor administered in the perioperative period * No objection to use of medical data Exclusion Criteria: \-
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Heparin-induced thrombocytopenia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Hôpital Universitaire La Pitié-Salpêtrière
Paris, 75013, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.